Skip to content

Plan for Microwave Thermal Field

Research on Intelligent System of Plan for Microwave Thermal Field for Hepatocellular Carcinoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05270642
Enrollment
5
Registered
2022-03-08
Start date
2021-10-01
Completion date
2022-12-30
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ablation, Hepatocellular Carcinoma

Keywords

hepatocellular Carcinoma, microwave ablation

Brief summary

Develop an intelligent system based on contrast-enhanced ultrasound and clinical information to help doctors automatically obtain ablation parameters (ablation needle number, ablation needle type, ablation time,ablation power) when preparing to use microwave ablation to treat hepatocellular carcinoma

Interventions

PROCEDUREMicrowave Thermal guided by Plan for Microwave Thermal Field system

When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Biopsy or clinical diagnosis of HCC 2. Complete clinical information and preoperative CEUS 3. Curative treatment

Exclusion criteria

1. Palliative care 2. Intolerance to ablation 3. Severe coagulation disorder

Design outcomes

Primary

MeasureTime frameDescription
local tumor progression6 monthsFollow up to observe whether local tumor progression occurs within 6 months after ablation
MRI within 3 days after ablationMRI within 3 days after ablationPostoperative MRI is used to determine whether the ablation zone completely covers the tumor and whether the size is appropriate

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026